"There is a good chance that, with the acceleration of clinical trials, there might be a #vaccine before the year end in reasonable quantities," Paul Stoffels, Vice Chair @JNJNews tells @richardquest as $JNJ begins Phase 1 of their #covid19 vaccine clinical trial. https://t.co/bV34pMg5M4